Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα.

Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα.

Item
http://www.wikidata.org/entity/Q39112113
Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular CarcinomaDrug activity screening based on microsomes-hydrogel system in predicting metabolism induced antitumor effect of oroxylin ACancer-selective cytotoxic Ca2+ overload in acute myeloid leukemia cells and attenuation of disease progression in mice by synergistically acting polyphenols curcumin and carnosic acid.Natural and Synthetic Flavonoids: Structure-Activity Relationship and Chemotherapeutic Potential for the Treatment of Leukemia.Hyperoside enhances the suppressive effects of arsenic trioxide on acute myeloid leukemia cellsOverview of Oroxylin A: A Promising Flavonoid Compound.Improved Survival With Integration of Chinese Herbal Medicine Therapy in Patients With Acute Myeloid Leukemia: A Nationwide Population-Based Cohort Study.PLSCR1/IP3R1/Ca2+ axis contributes to differentiation of primary AML cells induced by wogonoside.Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression.Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids.Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.UCP2-related mitochondrial pathway participates in oroxylin A-induced apoptosis in human colon cancer cells.Identification of cellular responses to low-dose radiation by the profiling of phosphorylated proteins in human B-lymphoblast IM-9 cells.Scutellaria baicalensis and Cancer Treatment: Recent Progress and Perspectives in Biomedical and Clinical Studies.Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells.
P2860

Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα.

Item
http://www.wikidata.org/entity/Q39112113
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Oroxylin A has therapeutic pot ...... ects targeting PPARγ and RXRα.
@en
Oroxylin A has therapeutic pot ...... ects targeting PPARγ and RXRα.
@nl
type
label
Oroxylin A has therapeutic pot ...... ects targeting PPARγ and RXRα.
@en
Oroxylin A has therapeutic pot ...... ects targeting PPARγ and RXRα.
@nl
prefLabel
Oroxylin A has therapeutic pot ...... ects targeting PPARγ and RXRα.
@en
Oroxylin A has therapeutic pot ...... ects targeting PPARγ and RXRα.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Oroxylin A has therapeutic pot ...... ects targeting PPARγ and RXRα.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921